Researchers from McGill University reviewed 26 RCTs comprising 15,491 participants investigating 12 GLP-1 RAs and co-agonists for treating obesity in adults without diabetes. Twelve GLP-1 RA ...

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 ... RA on kidney function in patients with moderate to advanced CKD, although ...

Adverse events were frequent (80 to 97% versus 63 to 100% for GLP-1 RA versus placebo); most were gastrointestinal-related, including nausea, vomiting, diarrhea, and constipation. "Our results ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...

Coya Therapeutics expands its pipeline, advancing COYA 303 with a dual immunomodulatory mechanism for inflammatory ... glucagon-like-peptide-1 receptor agonist (GLP-1 RA) designed for subcutaneous ...